Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRL3-ZUMAB in Advanced Solid Tumours
NCT04118114Phase 2Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Sep 2019
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PRL3-zumab in gastric cancer (GC), hepatocellular carcinoma (HCC) and solid tumor (advanced stage), sponsored by National Cancer Centre Singapore. Primary endpoints: Objective response rate up to 2 years, Number of patients that do not have disease progression at 16 weeks and 1 more. Started Sep 2019; status: completed.
02
Drugs
PRL3-zumab
03
Conditions
gastric cancer (GC)hepatocellular carcinoma (HCC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04118114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118114.